glp-1 agonists reduce inflammation The anti-inflammatory feature of glucagon-like peptide-1 and its based diabetes drugs—Therapeutic potential exploration in lung injury Anti-inflammatory role of glucagon-like peptide

Ill also give recommendations for those who are taking or are considering taking them for weight loss

[6] Related Articles Peptide Therapeutics: Current Status And Future Directions Anti-Cancer Peptide Drug Conjugates (PDCs): An Overview 9 Potential Blockbuster Drugs to be Approved in 2022

GIP (glucose-dependent insulinotropic polypeptide) is a hormone that may complement the effects of GLP-1 receptor agonists

4,7 In this regard, this addition ensures a more comprehensive discussion aligned with current expert consensus on risk mitigation strategies

The review also discusses emerging data in peripheral artery disease (e.g., STRIDE trial)

9 Notably, these agents have also led to a significant decrease in major cardiac events, regardless of their effect on blood glucose, indicating a dual benefit for both cardiac health and diabetes management